Is 2023 the year to add China to your core allocation?

  • Published
  • Length
    5 minute(s) read

China's financial markets experienced high volatility recently due to a regulatory crackdown, geopolitical tensions, and an economic slowdown triggered by a draconian zero-Covid policy. But 2023 – the Year of the Water Rabbit, a symbol of peace, a return to normal, and more – could open up a new chapter for Chinese equities and usher in plenty of opportunities, particularly in consumer-oriented sectors.


Chinese stocks delivered solid returns in 2020 but then fell sharply in 2021–2022 on the back of several policy decisions and other developments that fuelled foreign investors’ anxiety. These included tighter regulations for certain industries, the financial woes of real-estate giant Evergrande, and stricter transparency requirements for Chinese companies listed in the US. Not to mention Beijing’s strict zero-Covid policy and fears that China would invade Taiwan in the wake of Russia's invasion of Ukraine.

However, 2023 will be a year of normalization for China’s economy and financial markets, which could make its stocks an attractive allocation for investors. Here’s why global asset managers should consider adding Chinese equities to their portfolios.

A brighter future

Chinese assets experienced a massive sell-off in the past two years due to 5 risk factors: tighter regulatory scrutiny, especially of large internet firms, real estate crisis, zero-Covid policy, local politics and Sino-American tensions.

For the first four points, the signals have all turned green, as China has not only concluded this period of regulatory tightening, but has also shown support for the private sector, the Internet giants and the real estate sector. Moreover, the government has made concrete changes since the Party Congress in October.

The zero-Covid policy has been lifted and China opened back up on 8 January – somewhat abruptly, but the policy reversal was necessary and is good news for the country and the rest of the world. As for geopolitical tensions with the US, here the risks are still present given that the two countries will remain great rivals. US-China tensions which have jumped back after “Chinese Spy Balloon” incident would not see escalation in our view. We see economic recovery post-covid much powerful driver of Chinese equities in 2023.

Meanwhile, the US Public Company Accounting Oversight Board said it concluded its audit of a first batch of Chinese companies without incident and had secured access to inspect Chinese firms. This pushes off until 2025 the risk that Chinese companies could be delisted from US exchanges, and recent statements by US authorities make it increasingly possible that delistings could be avoided.

The news came just as leading Chinese policymakers, meeting at the China Economic Work Congress (the country’s biggest economic gathering), announced that boosting domestic demand would be a priority in 2023.

In light of China’s earlier-than-expected reopening, the continued easing of policy measures, and the government’s clear shift towards a pro-growth stance, we can expect China’s economy to ramp back up in 2023, although the speed of its reopening could cause some short-term difficulties. We now expect China’s GDP growth to pick up starting in the second quarter and to reach around 5.0% for the full year. This would make China the only major economy whose GDP growth is accelerating.


Sanguine growth prospects fuelled by domestic demand

An upturn in Covid infections will likely weigh on consumer spending in the first part of the year, but things are expected to improve as soon as the second quarter as Beijing implements its pro-growth and pro-consumption measures. Consumer spending will probably also be lifted by:

  • Higher household consumption fuelled by excess savings. Chinese households are now sitting on excess savings of nearly 18 trillion renminbi (2.5 trillion euros), including 4 trillion renminbi accumulated since 2020, largely as a result of pandemic lockdowns.

  • A job market recovery. Nearly one in five jobs in China is Covid-sensitive because it involves physical contact, which means that the lifting of the zero-Covid policy and the full reopening of China’s economy are likely to stimulate both supply (jobs) and demand (consumer spending). This should underpin a rebound in household consumption.

Other structural growth drivers for domestic demand in China include: a 1.4 billion-strong population; a per-capita GDP of over USD 12,500; a rising household consumption rate; and a five-fold increase in total household consumption between 2005 and 2020. In addition, if we look at household consumption as a percent of GDP, it appears that consumer spending in China, especially in rural areas, has substantial scope for expanding further. Household consumption is now 54.3% of GDP in China – relatively low compared to other major emerging countries and to developed countries (82.6% in the US1, for example), indicating considerable room for improvement.

All these factors point to a sustained increase in Chinese consumer spending. This should drive revenue growth for Chinese companies in consumer-oriented sectors for years to come.


Three other reasons to consider Chinese equities

The market is huge yet still under-represented and under-invested

The Chinese stock market – including A shares, H shares, ADRs, and S shares – has a combined market cap of over USD 19 trillion2, second only to the US, and more than 6,000 listed companies. It simply cannot be overlooked by investors today.

Yet despite the market’s size and momentum, Chinese equities are still under-represented in portfolio allocations and global equity indices. Chinese companies make up only around 3.6% of the MSCI All Country World Index, compared to 60.4% for US companies and 5.6% for Japanese ones. Foreign investors are 4% underweight Chinese domestic equities in their portfolios.

Chinese businesses are priced attractively

Even though the MSCI China Index is already up 35% from its October low3 on expectations of the country’s reopening, we’re still constructive on China since valuations are attractive. The MSCI China Index is trading at a price-to-earnings (P/E) ratio of around 11, slightly below its 10-year average, while global equities are trading at a P/E ratio of around 15.

In addition, we see positive earnings momentum. Unlike in the US, where earnings are expected to be weak, Chinese companies will probably experience an uptick in profits. Most Chinese companies have cut costs over the past three years, so top-line growth should drive an earnings recovery in 2023.

China offers portfolio diversification

Chinese equities can be an effective portfolio diversifier in terms of geographic exposure given their low correlation with other stock markets (that’s especially true for domestic A shares).


What’s more, Chinese society is rapidly becoming more digital, urban, innovative, and sustainability-focused – structural changes that equity investors can best take advantage of through thematic investments. We see particularly strong potential in four key areas of the new economy: 1) industrial and technological innovation; 2) healthcare; 3) ecological transition; and 4) consumption upgrade. This latter theme in particular could perform well in 2023 given the record level of Chinese household savings.


After 20 difficult months, 2023 could mark a new beginning for Chinese financial markets. It’s only a matter of time before China becomes a strategic asset class for international investors. However, there are some risks worth keeping an eye on (like an upswing in Covid infections and geopolitical developments), but we believe many of them can be mitigated through active portfolio management. At Carmignac, we’re convinced that a selective, benchmark-agnostic approach is essential for spotting the most attractive investment opportunities, particularly in China’s vast equity market. That’s why our Chinese investments are focused on our key convictions, which tend to differ from the holdings in the main Chinese equity indices.

1Sources: World Bank, final consumption expenditure % GDP
2Source : Bloomberg, CICC Research, 2022
3Source : Bloomberg, MSCI China Index return in USD from 31/10/2022 to 30/12/2022.

Learn more about investing in China:

Thank you for taking the time to provide your feedback, appreciated.

Marketing communication. Please refer to the KID/KIID, prospectus of the fund before making any final investment decisions. This document is intended for professional clients.

This material may not be reproduced, in whole or in part, without prior authorisation from the Management Company. This material does not constitute a subscription offer, nor does it constitute investment advice. This material is not intended to provide, and should not be relied on for, accounting, legal or tax advice. This material has been provided to you for informational purposes only and may not be relied upon by you in evaluating the merits of investing in any securities or interests referred to herein or for any other purposes. The information contained in this material may be partial information and may be modified without prior notice. They are expressed as of the date of writing and are derived from proprietary and non-proprietary sources deemed by Carmignac to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by Carmignac, its officers, employees or agents.

Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.

Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Access to the Funds may be subject to restrictions regarding certain persons or countries. This material is not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the material or availability of this material is prohibited. Persons in respect of whom such prohibitions apply must not access this material. Taxation depends on the situation of the individual. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA. The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital.

The Funds’ prospectus, KIDs, NAVs and annual reports are available at, or upon request to the Management Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive. The French investment funds (fonds communs de placement or FCP) are common funds in contractual form conforming to the UCITS or AIFM Directive under French law.

  • In France, Luxembourg, Sweden: The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital. The Funds’ prospectus, KIDs, NAV and annual reports are available at, or upon request to the Management.

  • In the United Kingdom: the Funds’ respective prospectuses, KIIDs and annual reports are available at, or upon request to the Management Company, or for the French Funds, at the offices of the Facilities Agent at BNP PARIBAS SECURITIES SERVICES, operating through its branch in London: 55 Moorgate, London EC2R. This document was prepared by Carmignac Gestion, Carmignac Gestion Luxembourg or Carmignac UK Ltd. FP Carmignac ICVC (the “Company”) is an Investment Company with variable capital incorporated in England and Wales under registered number 839620 and is authorised by the FCA with effect from 4 April 2019 and launched on 15 May 2019. FundRock Partners Limited is the Authorised Corporate Director (the “ACD”) of the Company and is authorised and regulated by the FCA. Registered Office: Hamilton Centre, Rodney Way, Chelmsford, Essex, CM1 3BY, UK; Registered in England and Wales with number 4162989. Carmignac Gestion Luxembourg SA has been appointed as the Investment Manager and distributor in respect of the Company. Carmignac UK Ltd (Registered in England and Wales with number 14162894) has been appointed as a sub-Investment Manager of the Company and is authorised and regulated by the Financial Conduct Authority with FRN:984288.

  • In Switzerland: the prospectus, KIDs and annual report are available at, or through our representative in Switzerland, CACEIS (Switzerland), S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Montrouge, Nyon Branch / Switzerland, Route de Signy 35, 1260 Nyon.

The Management Company can cease promotion in your country anytime. Investors have access to a summary of their rights in English on the following links: UK ; Switzerland ; France ; Luxembourg ; Sweden.